MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
NanoViricides Cash and Cash Equivalents 2011-2026 | NNVC
Annual Cash and Cash Equivalents NanoViricides
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.56 M | 4.8 M | 8.15 M | 14.1 M | 20.5 M | 13.7 M | 2.56 M | 7.08 M | 15.1 M | 24.2 M | 31.5 M | 36.7 M | 13.9 M | 14.3 M | 9.22 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.7 M | 1.56 M | 14.5 M |
Quarterly Cash and Cash Equivalents NanoViricides
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.15 M | 1.13 M | 1.56 M | 2.54 M | 3.96 M | 3.87 M | 4.8 M | 3.26 M | 5.25 M | 6.97 M | 8.15 M | 9.65 M | 11.4 M | 12.9 M | 14.1 M | 15.6 M | 17.3 M | 19.7 M | 20.5 M | 22.9 M | 18.4 M | 21.8 M | 13.7 M | 6.11 M | 708 K | 875 K | 2.56 M | 2.56 M | 3.9 M | 6.08 M | 7.08 M | 7.08 M | 12 M | 13.5 M | 12 M | 13.5 M | 19.3 M | 21.9 M | 19.3 M | 21.9 M | 28.2 M | 29.5 M | 28.2 M | 29.5 M | 35.3 M | 41.1 M | 35.3 M | 41.1 M | 16.9 M | 19.2 M | 16.9 M | 19.2 M | 13.9 M | 12.9 M | 13.9 M | 12.9 M | 12.1 M | 10.9 M | 12.1 M | 10.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.1 M | 708 K | 14.3 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Scholar Rock Holding Corporation
SRRK
|
324 M | $ 43.62 | -1.33 % | $ 5 B |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
3.22 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Avid Bioservices
CDMO
|
38.1 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Stoke Therapeutics
STOK
|
84.2 M | $ 33.98 | 0.83 % | $ 2.01 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.23 | -5.04 % | $ 314 M | Britain |
 |
EyePoint Pharmaceuticals
EYPT
|
102 M | $ 13.09 | 0.23 % | $ 959 K | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
China SXT Pharmaceuticals
SXTC
|
13.4 M | $ 1.38 | 4.55 % | $ 1.96 M | China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
966 B | $ 18.16 | 0.55 % | $ 28.4 B |  Japan |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
5.67 M | $ 1.07 | -2.29 % | $ 21.9 M | Israel |
 |
Enochian Biosciences
ENOB
|
92.7 K | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
30.3 M | $ 2.06 | - | $ 118 M | USA |
 |
Theravance Biopharma
TBPH
|
168 M | $ 14.97 | -1.45 % | $ 753 M | Cayman-islands |
 |
Eton Pharmaceuticals
ETON
|
25.9 M | $ 23.43 | -0.09 % | $ 630 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
348 M | $ 47.18 | -0.79 % | $ 4.24 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.46 | 0.22 % | $ 855 M | Canada |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |